Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enrasentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enrasentan SCHEMBL7636324 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8206689 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1031130 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1649828 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8008492 | 0.98 | EDNRA (0.97) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7660593 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7610103 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| SCHEMBL13038489 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL8203979 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL7538909 | 0.96 | EDNRA (0.92) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329810-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2024-02-22 | — | — | US | claimed |
| CN-117295520-A | Treatment of ocular diseases using endothelin receptor antagonists | 珀弗斯治疗股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2022232586-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-20260130890-A1 | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | PERFUSE THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622894-B2 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases | PERFUSE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11304936-B2 | Sulfasalazine salts, production processes and uses | MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH | 2022-04-19 | — | — | US | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220104548-A1 | AEROSOL DELIVERY DEVICES | CAMBRIDGE CONSULTANTS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220049306-A1 | CARDIOVASCULAR DISEASE | GENINCODE UK, LTD. (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-20260130890-A1 | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | VEGFA, PDE6D, EDNRA | EDNRA 3/4885EDNRB 7/4885 |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | RXRA, RXRG, RXRB | EDNRA 709/4885EDNRB 993/4885 |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | EDNRA 1/4885EDNRB 2/4885 |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | EDNRA 183/4885EDNRB 766/4885 |
| US-11304936-B2 | Sulfasalazine salts, production processes and uses | TPMT, SI, IL5 | EDNRA 2810/4885EDNRB 1927/4885 |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | EDNRA 4/4885EDNRB 5/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | EDNRA 463/4885EDNRB 1312/4885 |
| US-12622894-B2 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases | VEGFA, PDE6D, LGALS3 | EDNRA 28/4885EDNRB 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.